Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints
Statistical Methods in Medical Research · 2025
DOI: 10.1177/09622802251343599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistical Methods in Medical Research, 2025. Verfasst von Alan D Hutson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Endpoint Determination, Medical Oncology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Oncology clinical trials are increasingly expensive, necessitating efforts to streamline phase II and III trials to reduce costs and expedite treatment delivery. Randomization is often impractical in oncology trials due to small sample sizes and limited statistical power, leading to biased inferences. The FDA has recently published guidance documents encouraging the use of prognostic baseline measures to improve the precision of inferences around treatment effects. To address this, we propose an extension of Rosenbaum’s exact testing method incorporating a variant of martingale residuals for right censored data. This method can dramatically improve the statistical power of the test comparing treatment arms given time-to-event endpoints as compared to the standard log-rank test. Additionally, the modification of the martingale residual provides a straightforward metric for summarizing treatment effect by quantifying the expected events per treatment arm at each time-point. This approach is illustrated using a phase II clinical trial in small cell lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
ORCID-Profile: Alan D Hutson, Han Yu
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Hutson, A. D., & Yu, H. (2025). Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints. Statistical Methods in Medical Research. https://doi.org/10.1177/09622802251343599
Vancouver
Hutson AD, Yu H. Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints. Statistical Methods in Medical Research. 2025. doi:10.1177/09622802251343599
BibTeX
@article{Hutson2025,
author = {Hutson, Alan D and Yu, Han},
title = {Strategies to boost statistical efficiency in randomized oncology trials with primary time-to-event endpoints},
journal = {Statistical Methods in Medical Research},
year = {2025},
doi = {10.1177/09622802251343599}
}
EUVIMED